Management Team

Guy Miller, MD, PhD; Chief Executive Officer

Before forming Galileo, Dr. Miller was Associate Professor at Johns Hopkins Medical Institutions School of Medicine. After completing a Surgical Internship at the University of Chicago, he completed a residency in Anesthesiology & Critical Care Medicine and a Fellowship in Multidisciplinary Critical Care Medicine at Johns Hopkins. Currently, Dr. Miller is  Clinical Instructor, Stanford University School of Medicine. Dr. Miller holds an MD from the Medical College of Pennsylvania and a PhD in Chemistry from the University of Virginia.

Rob Lunbeck; Vice President, Chief Financial Officer

Mr. Lunbeck is responsible for Galileo's finance and accounting activities. Before joining Galileo, Mr. Lunbeck spent four years at Chase H&Q, an investment bank, where as Senior Analyst he covered certain specialty healthcare companies. Prior to Chase, Mr. Lunbeck spent five years in healthcare equity research at RCM Capital Management, a large San Francisco institutional money manager, where he was Analyst. Before joining RCM, Mr. Lunbeck worked four years in venture capital emphasizing biomedical investing at Security Pacific Capital Corporation, where he was Vice President. Mr. Lunbeck holds an MBA from the Stanford University Graduate School of Business and an AB in economics, Phi Beta Kappa, from Harvard College, and is a Chartered Financial Analyst. Before leaving to earn his MBA, Mr. Lunbeck completed half the four-year University of California, San Francisco School of Medicine curriculum.

Stephen F. Flaim, PhD, FACC; Vice President, Research & Development

Dr. Flaim is responsible for development and execution of Galileo's research and development strategies. Prior to joining Galileo, Dr. Flaim held faculty appointments in Medicine (Cardiology) and Physiology at the Pennsylvania State University College of Medicine at Hershey. Dr. Flaim joined McNeil Pharmaceutical, a subsidiary of the J&J Corporation, where he was responsible for cardiovascular drug discovery programs including angina and hypertension. He subsequently served as Associate Director of Cardiovascular Pharmacology at the Bristol-Myers Squibb Cardiovascular Research Institute where he directed drug discovery activities in ischemia, hypertension and arrhythmia. More recently, Dr. Flaim held the position of Vice President of Biological Sciences at Alliance Pharmaceutical Corp. where he was responsible for all preclinical activities. Additionally, Dr. Flaim served as Vice President of Biological Research & Development at Trega Biosciences, Inc. where he was responsible for drug discovery and development programs for obesity, metabolic diseases and pain management. Dr. Flaim holds a PhD in cardiovascular physiology from the University of California at Davis.

Stephen D. Phinney, MD, PhD; Vice President, Clinical Nutrition

Dr. Phinney is responsible for developing and managing clinical trials for Galileo's nutrition products. He has extensive experience in the design and conduct of clinical nutrition trials in both academic and industrial settings and has over 55 publications in the clinical nutrition and biochemistry literature. Dr. Phinney has clinical fellowship training in Clinical Nutrition at Harvard Medical School, has subsequently held clinical faculty appointments at MIT, University of Vermont College of Medicine, University of Minnesota, and was  Professor at University of California at Davis. Immediately prior to joining Galileo he worked as Senior Clinical Nutritionist for Monsanto (Calgene). Dr. Phinney holds a PhD from MIT in Nutritional Biochemistry and Metabolism and an MD from Stanford University.

Sekhar S. Boddupalli, PhD; Vice President, Nutrition Discovery

Dr. Boddupalli is responsible for the pre-clinical development of the company's nutrition products. After completing his doctoral training in biochemistry at the Indian Institute of Science in Bangalore, India, Dr. Boddupalli held faculty appointments in Biochemistry at the University of Texas Southwestern Medical Center in Dallas, Texas. Upon leaving academia, Dr. Boddupalli joined Cregen Biotechnology, a subsidiary of the Monsanto Company, where he was responsible for discovery and development projects for the alteration of food quality traits in agronomic crops for animal and human nutritional uses. He subsequently served as a member of the Agriculture Sector team for Monsanto's India Global Business Development effort where he promoted the development of the company's business in India. Most recently, Dr. Boddupalli held the position of Director of Human Nutrition at Monsanto where he was responsible for developing and implementing technology strategy towards expanding crop biotechnology into human nutrition, food, and feed.

Peter Leighton; Vice President, Marketing

Mr. Leighton is responsible for marketing Galileo's nutrition products and for corporate marketing communications. Mr. Leighton has over 15 years experience in management and strategic marketing. Working with such companies as Lichtwer Pharma, Imagine Foods, Natrol, Natural Balance, InterHealth Nutraceuticals and Weider Nutrition, Mr. Leighton was responsible for successfully launching and developing notable nutritional brands such as CitriMax™ (the world's best selling HCA diet nutraceutical), ActiVin™ (leading GSE antioxidant), Kavatrol^®, Iprical™, and Schiff^® brand dietary supplements. Mr. Leighton is also a contributing writer for many nutrition industry publications including Nutraceuticals World, Frozen Food Age, Gourmet Retailer and Health Products Business, and frequently lectures at industry events. Prior to joining Galileo, Mr. Leighton served as Senior Vice President of Marketing for Weider Nutrition International.

Carol Stratford, PhD, JD; Vice President, Intellectual Property

Dr. Stratford is responsible for management and strategy of Galileo's intellectual property. Dr. Stratford has over 10 years experience in biotechnology patent prosecution. Before joining Galileo, she was Director of Patents at Elan Pharmaceuticals where she was involved in patent strategy and licensing activities. Prior to her work at Elan, she was a partner in the biotech law firm of Dehlinger & Associates LLP. Dr. Stratford served on the founding Scientific Advisory Board of Neurex Corporation (now Elan Pharmaceuticals) and also worked there in the company's formative years as a scientist and research manager. Dr. Stratford holds BS and MA degrees from Stanford University, a PhD in Pharmacology from the University of Michigan and a JD from Santa Clara University School of Law, where she was one of the first recipients of High Technology Certification in Law. She carried out postdoctoral research at Stanford University and has taught courses in biotechnology law at Santa Clara University.